Food and Drug Administration
The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency's work affects Americans' health and safety.
Guests
reporter on the national desk of "The Washington Post"
author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
(R-Iowa), ranking member of the Senate Finance Committee
deputy director of the FDA's Office of New Drugs
Please familiarize yourself with our Code of Conduct and Terms of Use before posting your comments.

